Publications by authors named "Masaru Baba"

Claim this Profile
T
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Masatsugu Ohara, Goki Suda, Risako Kohya, Yutaka Yasui, Kaoru Tsuchiya, Masaru Baba

Hepatol Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.
Goki Suda, Masaru Baba, Yoshiya Yamamoto, Sonoe Yoshida, Tetsuhito Muranaka

Sci Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study.
Goki Suda, Masaya Sugiyama, Hayato Hikita, Akira Nishio, Tomohide Tatsumi, Masaru Baba

Biomark Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.
Risako Kohya, Goki Suda, Masatsugu Ohara, Shunichi Hosoda, Takuya Sho, Masaru Baba

JHEP Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.
Zijian Yang, Goki Suda, Takuya Sho, Osamu Maehara, Masatsugu Ohara, Masaru Baba

Hepatol Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cefiderocol susceptibility of 146 Stenotrophomonas maltophilia strains clinically isolated from blood in two Japanese hospitals over a 10-year period.
Takashi Sakoh, Emiko Miyajima, Yusuke Endo, Masaru Baba, Mizuki Haraguchi

Eur J Clin Microbiol Infect Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.
Naohiro Yasuura, Goki Suda, Masatsugu Ohara, Akimitsu Meno, Takuya Sho, Masaru Baba

Aliment Pharmacol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution of Fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction-associated steatotic liver disease in health check-up.
Yuji Ogawa, Wataru Tomeno, Yasushi Imamura, Masaru Baba, Takato Ueno

Hepatol Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
Takuya Sho, Goki Suda, Masatsugu Ohara, Risako Kohya, Takashi Sasaki, Masaru Baba

Target Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Helicobacter fennelliae Localization to Diffuse Areas of Human Intestine, Japan.
Takashi Sakoh, Emiko Miyajima, Yusuke Endo, Kei Kono, Junichiro Sato, Masaru Baba

Emerg Infect Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
Shunichi Hosoda, Goki Suda, Takuya Sho, Koji Ogawa, Megumi Kimura, Masaru Baba

Liver Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
Goki Suda, Masaru Baba, Yoshiya Yamamoto, Takuya Sho, Koji Ogawa

J Med Virol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
Naoki Kawagishi, Goki Suda, Yoshiya Yamamoto, Masaru Baba, Ken Furuya

Viruses· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Universal admission screening for COVID-19 using quantitative antigen testing and questionnaire screening to prevent nosocomial spread.
Masayo Morishima, Muneyoshi Kimura, Takashi Sakoh, Ryosuke Yamamuro, Sho Ogura, Masaru Baba

PLoS One· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.
Naoki Kawagishi, Goki Suda, Ryotaro Sakamori, Takeshi Matsui, Masahiro Onozawa, Masaru Baba

Sci Rep· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.
Takuya Sho, Goki Suda, Yoshiya Yamamoto, Ken Furuya, Masaru Baba

Cancers (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated with Breakthrough Fungemia Caused by , , or Fusarium Species in Patients with Hematological Disorders.
Muneyoshi Kimura, Yuki Asano-Mori, Takashi Sakoh, Masahiro Abe, Keigo Ueno, Masaru Baba

Antimicrob Agents Chemother· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
Masato Nakai, Yoshiya Yamamoto, Masaru Baba, Goki Suda, Akinori Kubo

Sci Rep· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of liver scintigraphy and the liver-spleen contrast in Gd-EOB-DTPA-enhanced MRI on liver function tests.
Hiroshige Mori, Hanaka Machimura, Amika Iwaya, Masaru Baba, Ken Furuya

Sci Rep· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
Taku Shigesawa, Goki Suda, Megumi Kimura, Osamu Maehara, Yoshimasa Tokuchi, Masaru Baba

PLoS One· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
Takuya Sho, Goki Suda, Koji Ogawa, Megumi Kimura, Akinori Kubo, Masaru Baba

Hepatol Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reverse Transcription Loop-Mediated Isothermal Amplification Assay-Based Infection Control Strategies for COVID-19 in a Hospital Under the State of Emergency in Tokyo, Japan in Spring 2020.
Muneyoshi Kimura, Masaru Baba, Shunichiro Maruyama, Sho Ogura, Ryosuke Yamamuro

Jpn J Infect Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
Kazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, Ken Furuya, Masaru Baba

J Gastroenterol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.
Takuya Sho, Goki Suda, Koji Ogawa, Taku Shigesawa, Kazuharu Suzuki, Masaru Baba

Hepatol Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.
Takuya Sho, Goki Suda, Koji Ogawa, Megumi Kimura, Tomoe Shimazaki, Masaru Baba

JGH Open· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis